Tekmira (TKMR) IND for TKM-Ebola Receives FDA Approval
Tweet
Share
E-mailGet Alerts TKMR Hot Sheet
Join SI Premium – FREE
Tekmira Pharmaceuticals Corporation (Nasdaq: TKMR) reports its Investigational New Drug (IND) application for TKM-Ebola has been approved by the United States Food and Drug Administration (FDA) allowing Tekmira to initiate a Phase 1 clinical trial.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Health Canada approves Sunshine Biopharma's generic Atenolol tablets
- Ecopetrol formalizes board of directors candidate slate
- Ensysce completes enrollment in final stage of opioid study
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
